CDSCO approves extension of shelf life for Covaxin

The longer shelf life is expected to help optimise and improve the use of vaccine.

127
CDSCO DCGI FDA

Last Updated on November 4, 2021 by The Health Master

The drug regulator of India has approved the extension of shelf life of Bharat Biotech‘s Covid-19 vaccine Covaxin up to 12 months.

The company today announced that it has received the approval from the Central Drugs Standard Control Organisation (CDSCO) for the extension of shelflife of the vaccine up to 12 months, from the date of manufacture.

“This approval of shelf life extension is based on the availability of additional data, which was submitted to CDSCO,” added the Hyderabad-based company.

The vaccine was initially approved by the drug regulator for a shelf life of six months, when stored at two to eight degree celsius. It was later extended to nine months.

The longer shelf life is expected to help optimise and improve the use of vaccine.

Covishield

Covaxin

Sputnik V

Modenra

Pharma sector seek Govt to decriminalize errors by Drug Mfrs in…

Latest Anti-counterfeiting packaging for Pharma Sector

Why Indians have more trust their nearby Medical Store

USFDA nod for Cortrophin Gel to treat Autoimmune Disorders

WHO approves Indian Firm Bharat Biotech’s Covaxin

FDA cancels licenses of 2 Blood Cantres, suspends 12 firms

Duties of Retail Chemists / Medical Store / Pharmacy

Govt to plan to conduct these 8 studies on Pharma & Medical Devices

Govt takes important decisions on Pharma & Medical Devices Industry

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner